" class="no-js "lang="en-US"> Wyss Center Geneva Appoints Erwin Böttinger as New CEO
Wednesday, June 19, 2024

Wyss Center Geneva Appoints Erwin Böttinger as New Chief Executive Officer

The Executive Board of the Wyss Center for Bio and Neuroengineering, a non-profit research center, is pleased to announce the appointment of Professor Erwin Böttinger as its new Chief Executive Officer (CEO). The appointment follows a funding commitment of CHF 120 million from the Wyss Foundation to further strengthen the Center’s mission to accelerate innovative therapies to the clinic to transform the lives of people with brain disorders.

Professor Steven E. Hyman, MD, Director, Stanley Center for Psychiatric Research at the Broad Institute and Co-Chair of the Wyss Center Executive Board: “Erwin is a pioneer in life science research and a visionary and experienced leader in translating promising technologies to improve patient care. Since its founding, the Wyss Center has developed strong systems to advance vital technologies to the clinic. Erwin’s appointment will accelerate these translational efforts so that I look forward to seeing new diagnostics and therapies that will transform many lives in the years to come.”

Prof. Erwin Böttinger: “I am proud and privileged to lead the Wyss Center and to focus on making a real difference to the lives of people with neurological and mental health disorders. We have a bold plan to innovate and accelerate transformational technologies in artificial intelligence, bio- and neuroengineering to restore essential neural functions or reset abnormal neural circuits in people with devastating brain disorders. Together with our partners from the École Polytechnique Fédérale de Lausanne, the University of Geneva and Geneva University Hospital, the Wyss Center is poised to catalyze the unique concentration of world-class brain health research at Campus Biotech to drive clinical breakthroughs.”

Campus Biotech is a neuroscience and innovation center of excellence in Geneva, Switzerland, that provides a collaborative environment in advanced research facilities, as well as space for start-ups and industrial partnerships.

Prof. Böttinger has a longstanding track record in personalized medicine, with emphasis on genomics and digital technologies. Before joining the Wyss Center, he was instrumental in building the Charles Bronfman Institute for Personalized Medicine and the Hasso Plattner Institute for Digital Health at Mount Sinai, at the Icahn School of Medicine at Mount Sinai in New York City, both with a strong translational focus. He also served as founding director of the Digital Health Center at the Hasso Plattner Institute for Digital Engineering and University Potsdam, and as CEO of the Berlin Institute of Health, Berlin, Germany.

  1. Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
  2. Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
  3. DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
  4. Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
  5. Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more